CAN PERIMENOPAUSE CAUSE DEPRESSION?
By Alexis Anderson, DO
California Psychiatrist | Hormone-Informed Care for Women in Midlife
The short answer is yes: perimenopause can be a period of increased vulnerability to depressive symptoms and major depressive episodes. But that does not mean every episode of depression in midlife is caused by hormones—or that symptoms should be dismissed as “just menopause.”
Perimenopause occurs during a complicated stage of life. Reproductive hormones are fluctuating, sleep may be disrupted, physical symptoms may be emerging, and many women are simultaneously navigating demanding careers, caregiving, parenting, changing relationships, health concerns, grief, or questions about identity and aging.
The biology matters. So does the rest of a woman’s life.
Understanding how these factors intersect is central to a thoughtful psychiatric evaluation.
What Can Depression During Perimenopause Feel Like?
Depression does not always look like sadness. During perimenopause, women may describe:
Loss of interest or pleasure
Persistent sadness, emptiness, or hopelessness
Irritability or feeling unusually reactive
Reduced motivation
Fatigue or a sense of moving through mud
Difficulty concentrating or making decisions
Sleep disruption
Changes in appetite
Feelings of guilt, inadequacy, or worthlessness
Withdrawing from relationships or activities
Feeling unlike themselves
Thoughts of death or suicide
Some of these experiences—particularly changes in sleep, energy, attention, and memory—can also occur with other medical conditions, medication effects, stress, or menopause symptoms that do not meet the criteria for depression.
This overlap is one reason a careful evaluation matters.
Why Can Depression Emerge or Worsen During Perimenopause?
Estrogen does more than regulate reproduction. It interacts with brain systems involved in mood, sleep, cognition, stress response, and emotional regulation.
During perimenopause, estrogen levels do not simply decline in a smooth, predictable line. They can fluctuate considerably. Researchers believe that some women may be particularly sensitive to this hormonal variability.
Research identifies the menopausal transition as a potential window of vulnerability to depressive symptoms and major depressive episodes, particularly for women with a previous history of depression. The degree of risk varies considerably, however, and women are not universally or uniformly vulnerable.
A previous history of depression is one of the strongest predictors of depression during the menopausal transition, and recurrence appears to account for much of the increased risk. Whether perimenopause independently increases the risk of a first-lifetime major depressive episode remains less certain.
Some prospective studies have found an increase in new-onset depressive symptoms among women without a previous history of depression. Other findings suggest that first episodes are more strongly associated with factors such as anxiety, physical illness, impaired functioning, and stressful life circumstances. A first episode can occur during perimenopause, but it should not automatically be attributed to hormonal change.
Other factors associated with greater vulnerability may include:
A history of significant premenstrual mood symptoms or PMDD
Depression associated with pregnancy or the postpartum period
Distressing hot flashes or night sweats
Persistent insomnia
Major psychosocial stress
Trauma or adverse life experiences
Limited social support
Significant medical illness
These factors can overlap. For example, night sweats may disrupt sleep, impaired sleep may reduce emotional resilience, and existing stress may become more difficult to manage. Depression during perimenopause is often better understood as an interaction among biological, psychological, medical, and social influences than as the result of one isolated cause.
Is It Depression, Menopause, or Something Else?
This is often the most important question—and the answer may be more than one thing.
Sleep disruption from night sweats can affect energy, concentration, emotional regulation, and resilience. Thyroid disease, anemia, medication effects, substance use, chronic pain, and other medical problems can produce or worsen symptoms that resemble depression.
Grief, relationship difficulties, caregiving demands, work stress, and changing family roles can also contribute. Anxiety, ADHD, bipolar disorder, and other psychiatric conditions may overlap with or be mistaken for depression.
It is also important to distinguish depressive symptoms from a major depressive episode. A woman may experience intermittent low mood, irritability, reduced energy, or disrupted sleep without meeting the diagnostic criteria for major depression. Conversely, significant depression should not be minimized simply because it arose during perimenopause.
Hormone-informed psychiatric care does not assume that hormones explain everything. Instead, it asks how reproductive stage and hormonal symptoms may fit within the larger biological, psychological, medical, and social picture.
How Is Perimenopausal Depression Evaluated?
A comprehensive psychiatric evaluation may include:
Current mood, anxiety, sleep, and cognitive symptoms
The severity, duration, and timing of symptoms
Changes in menstrual patterns and other menopause symptoms
Previous depressive or mood episodes
Premenstrual, pregnancy, and postpartum psychiatric history
Current and previous medications
Existing menopause hormone therapy
Medical conditions and relevant laboratory evaluation
Alcohol, cannabis, and other substance use
Family psychiatric history
Trauma, relationships, stress, and life circumstances
Current functioning and safety
Personal treatment preferences and goals
Validated screening questionnaires can be helpful, but they do not replace a clinical evaluation. The goal is not simply to assign every symptom to either “psychiatry” or “hormones.” The goal is to understand how the different pieces may be interacting.
How Is Depression During Perimenopause Treated?
Treatment should be individualized according to the diagnosis, symptom severity, medical history, reproductive stage, previous treatment response, and the woman’s preferences.
Psychotherapy
Psychotherapy can address both depressive symptoms and the psychological demands of midlife.
Cognitive behavioral therapy can help identify patterns that reinforce depression and develop practical strategies for mood, sleep, stress, and behavior. Psychodynamic psychotherapy can help women understand how past experiences, relationships, identity, loss, self-worth, and life transitions are shaping their current emotional lives.
For many women, the therapeutic relationship also provides something that fragmented care cannot: a consistent place to understand how biology and personal history are interacting over time.
Psychiatric medication
Antidepressants and psychotherapy are established first-line treatments for a major depressive episode during perimenopause.
Medication selection depends on the individual. A psychiatrist may consider the nature of the symptoms, previous medication response, side effects, sleep, anxiety, hot flashes, medical history, other medications, and the possibility of bipolar disorder.
Medication should not be selected solely because a patient is in perimenopause. It should be chosen as part of a complete psychiatric and medical assessment.
Menopause hormone therapy
Menopause hormone therapy, or MHT, is not an antidepressant and is not approved specifically as a treatment for depression. Research nevertheless suggests that estrogen may have antidepressant effects for some perimenopausal women, particularly when depression occurs alongside vasomotor symptoms such as hot flashes and night sweats.
Research in this area requires careful interpretation. Trials have studied different populations, hormonal regimens, reproductive stages, and outcomes. Evidence concerning transdermal estradiol during perimenopause should not be generalized to every woman, every form of MHT, or depression after menopause.
MHT is therefore not a universal treatment for perimenopausal depression or a substitute for appropriate psychiatric care. Decisions about MHT require an individualized assessment of symptoms, reproductive stage, medical history, risks, benefits, and personal preferences.
I do not prescribe MHT. When appropriate and with the patient’s permission, I coordinate with her OB/GYN, primary care physician, or menopause specialist so that psychiatric treatment and hormonal care are not considered in isolation.
Sleep and physical symptoms
Sleep deserves direct attention. Insomnia can worsen mood, concentration, anxiety, irritability, and the ability to cope with stress.
Treatment may therefore include evaluating the causes of disrupted sleep, addressing psychiatric contributors, and coordinating care for hot flashes, night sweats, sleep apnea, pain, or other medical conditions.
Exercise, nutrition, social connection, reduced alcohol use, and consistent sleep routines can support recovery and overall health. They are valuable components of care, but a person with significant depression should not be told that lifestyle changes alone are necessarily sufficient.
When Should You Seek Psychiatric Care?
Consider seeking an evaluation when symptoms:
Persist rather than passing quickly
Interfere with work, relationships, parenting, or daily functioning
Make it difficult to experience pleasure or connection
Cause significant sleep or appetite changes
Feel different from previous menopause symptoms
Are worsening despite support or self-care
Include hopelessness, worthlessness, or thoughts of death
Raise concern about bipolar disorder or another psychiatric condition
You do not need to determine on your own whether the problem is “hormonal enough” or “psychiatric enough” to deserve care. That is part of what a comprehensive evaluation is designed to explore.
When to Seek Urgent Help
Thoughts of suicide, feeling unable to remain safe, severe agitation, psychosis, or an inability to care for yourself require immediate attention.
In the United States, call or text 988 to reach the 988 Suicide & Crisis Lifeline. If you or someone else is in immediate danger, call 911 or go to the nearest emergency department.
The Most Important Takeaway
Perimenopause can be a genuine period of vulnerability to depression, particularly for women with a previous history of depressive illness. The evidence concerning first-lifetime depression is more mixed, and hormonal changes are only one part of the picture.
Effective care begins by taking symptoms seriously and considering the whole person: psychiatric history, reproductive stage, sleep, physical health, medications, relationships, stress, and lived experience.
Women should not have to choose between being told that everything is hormonal and being told that hormones are irrelevant. Thoughtful care makes room for both biology and biography.
About the Author
Alexis Anderson, DO, is a California psychiatrist providing hormone-informed psychiatric care for women during perimenopause and menopause. She completed adult psychiatry residency training at Yale University and child and adolescent psychiatry fellowship training at the University of California, San Francisco. Since 2008, she has provided integrated psychotherapy and psychiatric medication management in private practice. Learn more about Dr. Anderson’s approach to concierge psychiatry for women in midlife.
Looking for hormone-informed psychiatric care during perimenopause? Learn about perimenopause and menopause psychiatric care for women throughout California.
References
Maki PM, Kornstein SG, Joffe H, et al. Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations. Menopause. 2018;25(10):1069–1085. PubMed
Bromberger JT, Kravitz HM, Chang YF, et al. Major depression during and after the menopausal transition: Study of Women’s Health Across the Nation (SWAN). Psychological Medicine. 2011;41(9):1879–1888. PubMed
Freeman EW, Sammel MD, Lin H, Nelson DB. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Archives of General Psychiatry. 2006;63(4):375–382. PubMed
Cohen LS, Soares CN, Vitonis AF, Otto MW, Harlow BL. Risk for new onset of depression during the menopausal transition: the Harvard Study of Moods and Cycles. Archives of General Psychiatry. 2006;63(4):385–390. PubMed
Soares CN, Almeida OP, Joffe H, Cohen LS. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Archives of General Psychiatry. 2001;58(6):529–534. JAMA Psychiatry
Gordon JL, Rubinow DR, Eisenlohr-Moul TA, Xia K, Schmidt PJ, Girdler SS. Efficacy of transdermal estradiol and micronized progesterone in the prevention of depressive symptoms in the menopause transition: a randomized clinical trial. JAMA Psychiatry. 2018;75(2):149–157. PubMed
National Institute for Health and Care Excellence. Menopause: identification and management. NICE Guideline NG23. Updated 2026. NICE recommendations
This article is for educational purposes and does not provide individual medical advice or establish a physician-patient relationship. Treatment decisions should be made with a qualified healthcare professional who can evaluate your individual circumstances.